At this market cap, to have a drug that has been objectively assessed via biomarkers (albeit not statistically significant yet) to be a disease modifying drug for a neurological disorder with no current treatment is as good as it gets imo. The 201 readout next year is going to be a watershed moment for MSA sufferers I think.
This can be a US500 M net annual sales drug within 5 years if the science continues to play out....
- Forums
- ASX - By Stock
- ATH
- Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-74
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $15.96M |
Open | High | Low | Value | Volume |
0.3¢ | 0.4¢ | 0.3¢ | $11.18K | 3.279M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
38 | 52064257 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 126697935 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
38 | 52064257 | 0.003 |
61 | 90168098 | 0.002 |
27 | 122861099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 126697935 | 22 |
0.005 | 31010632 | 27 |
0.006 | 12348927 | 17 |
0.007 | 47851651 | 23 |
0.008 | 20165275 | 23 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |